NasdaqGS - Nasdaq Real Time Price USD

Incyte Corporation (INCY)

51.65

-0.27

(-0.52%)

At close: 4:00 PM EDT

51.65

+0.02

(+0.04%)

After hours: 4:04 PM EDT

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 6 hours ago

INCY
-0.52%
GILD
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

Zacks 6 hours ago

INCY
-0.52%
NVS
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

WILMINGTON, Del. & SAN DIEGO, April 23, 2024--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

Business Wire 9 hours ago

INCY
-0.52%
The past three years for Incyte (NASDAQ:INCY) investors has not been profitable

For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...

Simply Wall St. 8 days ago

INCY
-0.52%
Certain Biotech Investors Get an Early Look at Results. Is That Fair?

Private investments in public equities, or PIPEs, are all the rage in biotech, but some investors resent the sharing of nonpublic information.

The Wall Street Journal 8 days ago

TSHA

INCY
-0.52%
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks 11 days ago

INCY
-0.52%
Incyte to Report First Quarter Financial Results

WILMINGTON, Del., April 11, 2024--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024.

Business Wire 12 days ago

INCY
-0.52%
Biotech Executive Who Bet on Rival’s Stock Committed Insider Trading, Jury Says

A biotech executive committed insider trading when he bet on a competitor’s stock, believing the shares would rise when news about his own company hit the market, a jury found Friday. The civil-fraud verdict against Matthew Panuwat, former head of business development for pharmaceutical company Medivation, marks a significant expansion of insider-trading law. The law has mostly been used to punish people who misuse nonpublic information by buying or selling their company’s stock before a big share-price move—or tipping others to do so.

The Wall Street Journal 17 days ago

INCY
-0.52%
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

WILMINGTON, Del. and HONG KONG, April 01, 2024--Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Business Wire 22 days ago

INCY
-0.52%
12 Best S&P 500 Stocks To Buy According to Analysts

In this piece, we will take a look at the 12 best S&P 500 stocks to buy according to analysts. If you want to skip our coverage of the latest happenings surrounding one of America’s most widely followed stock indexes, then you can take a look at the 5 Best S&P 500 Stocks To Buy […]

Insider Monkey 23 days ago

^GSPC

NVDA

CUK
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., March 29, 2024--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 24 days ago

INCY
-0.52%
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.

Zacks 27 days ago

MSB.AX

INCY
-0.52%
NVS
SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive

(Bloomberg) -- A lawyer for the US Securities and Exchange Commission told a jury that a former biotech executive’s $120,000 windfall on a trade in a competing company’s stock was “like betting on a game when you know who’s going to win” because he knew the pending takeover of his firm would likely boost its rival.Most Read from BloombergTrump’s Net Worth Hits $6.5 Billion, Making Him One of World’s 500 Richest PeopleBiden Gains Ground Against Trump in Six Key States, Poll ShowsTrump Vows to Pay

Bloomberg 28 days ago

PFE

INCY
-0.52%
30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]

Insider Monkey last month

ILMN
+3.50%
AZN

EXEL
+1.84%
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

INCY
-0.52%
QGEN
Incyte (INCY) Posts Positive Results on Opzelura From HS Study

Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.

Zacks last month

INCY
-0.52%
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead

The allure of penny stocks is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares. And if the stock moves just a nickel or dime higher, you can make a killing that sets you up for life. Unfortunately, that’s not the way most penny stocks work. They are just as likely (if not more) to be pump-and-dump scams as they are real companies trying to make their way. Often they won’t even have a product or service available. They are just a story, typic

InvestorPlace last month

PYPL

JD

INCY
-0.52%
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

WILMINGTON, Del., March 10, 2024--Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

Business Wire last month

INCY
-0.52%
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

WILMINGTON, Del., March 10, 2024--Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

Business Wire last month

INCY
-0.52%
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise

The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes. The IQVIA Institute’s report addressed the productivity of clinical development and efforts to improve racial and ethnic representation in clinical trials. Despite advancements, the ecosystem faces challenges, like disparities in patient access to novel cancer medicines across different regions. Moreover, the financial

InvestorPlace last month

MRNA

INCY
-0.52%
ILMN
+3.50%

Performance Overview

Return	INCY	S&P 500
YTD	-17.74%	+6.30%
1-Year	-30.75%	+22.67%
3-Year	-38.64%	+22.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Incyte Corporation (INCY)

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

The past three years for Incyte (NASDAQ:INCY) investors has not been profitable

Certain Biotech Investors Get an Early Look at Results. Is That Fair?

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Incyte to Report First Quarter Financial Results

Biotech Executive Who Bet on Rival’s Stock Committed Insider Trading, Jury Says

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

12 Best S&P 500 Stocks To Buy According to Analysts

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive

30 Biggest Biotechnology Companies in the World

Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?

Incyte (INCY) Posts Positive Results on Opzelura From HS Study

Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise

Performance Overview